Drug Profile
Mecripyrine hydrochloride - Simcere/YenePharma
Alternative Names: SCR-1693; Y-1Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Simcere Pharmaceutical Group; YenePharma
- Developer YenePharma
- Class Antidementias; Neuroprotectants
- Mechanism of Action Acetylcholinesterase inhibitors; Calcium channel antagonists; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in China (PO, Tablet)
- 14 Nov 2017 Phase-I clinical trials in Alzheimer's disease (In volunteers) in China (PO) (ChiCTR1800016198)